{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:58:41Z","timestamp":1758477521508},"reference-count":45,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2019,4,10]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Since the last two decades, there has been more focus on the\ndevelopment strategies related to Anti-Alzheimer\u2019s drug research. This may be attributed to the\nfact that most of the Alzheimer's cases are still mostly unknown except for a few cases, where\ngenetic differences have been identified. With the progress of the disease, the symptoms involve\nintellectual deterioration, memory impairment, abnormal personality and behavioural patterns,\nconfusion, aggression, mood swings, irritability Current therapies available for this disease give\nonly symptomatic relief and do not focus on manipulations of biololecular processes.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> Nearly all the therapies to treat Alzheimer's disease, target to change the amyloid\ncascade which is considered to be important in AD pathogenesis. New drug regimens are not able\nto keep pace with the ever-increasing understanding about dementia at the molecular level.\nLooking into these aggravated problems, we thought to put forth molecular modeling as a drug\ndiscovery approach for developing novel drugs to treat Alzheimer disease. The disease is incurable\nand it gets worst as it advances and finally causes death. Due to this, the design of drugs to treat\nthis disease has become an utmost priority for research. One of the most important emerging\ntechnologies applied for this has been Computer-assisted drug design (CADD). It is a research tool\nthat employs large-scale computing strategies in an attempt to develop a model receptor site which\ncan be used for designing of an anti-Alzheimer drug.\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Various models of amyloid-based calcium channels have been computationally optimized.\nDocking and De novo evolution are used to design the compounds. They are further subjected to\nabsorption, distribution, metabolism, excretion and toxicity (ADMET) studies to finally bring\nabout active compounds that are able to cross BBB. Many novel compounds have been designed\nwhich might be promising ones for the treatment of AD.\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> The present review describes the research carried out on various heterocyclic\nscaffolds that can serve as lead compounds to design Anti-Alzheimer\u2019s drugs in the future. The\nmolecular modeling methods can thus become a better alternative for the discovery of newer Anti-\nAlzheimer agents. This methodology is extremely useful to design drugs in minimum time with\nenhanced activity keeping balanced ethical considerations. Thus, the researchers are opting for this\nimproved process over the conventional methods hoping to achieve a sure shot way out for the\nsufferings of people affected by Alzheimer besides other diseases.&lt;P&amp;gt;<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570163815666180417120833","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T06:38:17Z","timestamp":1524033497000},"page":"66-73","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Methodologies Related to Computational Models in View of Developing Anti-Alzheimer Drugs: An Overview"],"prefix":"10.2174","volume":"16","author":[{"given":"Kirtee","family":"Baheti","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Government College of Pharmacy, Aurangabad-431005, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayura","family":"Kale","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Government College of Pharmacy, Aurangabad-431005, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.2174\/092986708785909030","volume":"15","author":"Copani A.","year":"2013","unstructured":"Copani A, Guccione S, Giurato L.  The cell cycle molecules behind neurodegeneration in Alzheimers disease: Perspectives for drug development.","journal-title":"Curr Med Chem"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.3390\/molecules17033524","volume":"17","author":"Yoo K.Y.","year":"2012","unstructured":"Yoo KY, Park SY.  Terpenoids as potential anti-alzheimer\u2019s disease therapeutics.","journal-title":"Molecules"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2202-14-44","volume":"14","author":"Sandra S.","year":"2013","unstructured":"Sandra S, Lorenzini L, Giuliani A.  Multi-target action of the novel anti-Alzheimer compound CHF5074:  study of long term treatment in Tg2576 mice.","journal-title":"BMC Neurosci"},{"key":"ref=4","first-page":"19","volume":"11","author":"Wang Y.J.","year":"2006","unstructured":"Wang YJ, Zhou HD, Zhou XF.  Clearance of amyloid-beta in Alzheimer\u2019s disease: progress, problems and perspectives.","journal-title":"Drug Discov Today"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1749-6632.2000.tb06412.x","volume":"903","author":"Aguero-Torres H.","year":"2000","unstructured":"Aguero-Torres H, Winblad B.  Alzheimer\u2019s disease and vascular dementia. Some points of confluence.","journal-title":"Ann N Y Acad Sci"},{"key":"ref=6","first-page":"1","volume":"58","author":"Woodward M.C.","year":"2012","unstructured":"Woodward MC.  Drug treatments in development for Alzheimer\u2019s disease.","journal-title":"J Pharm Pract Res"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1016\/j.bmc.2013.05.028","volume":"21","author":"Keri R.S.","year":"2013","unstructured":"Keri RS, Quintanova C, Marques SM, Esteves AR, Cardoso SM, Santos MA.  Design, synthesis and neuroprotective evaluation of novel tacrinee-benzothiazole hybrids as multi-targeted compounds against Alzheimer\u2019s disease.","journal-title":"Bioorg Med Chem"},{"key":"ref=8","first-page":"30","volume":"3","author":"Abdelwahab S.I.","year":"2013","unstructured":"Abdelwahab SI.  \n                         inhibitory effect of Boeserngin A on human acetylcholinestrase: Understanding its potential using  ADMET studies.","journal-title":"J Appl Pharm Sci"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/156802606775193293","volume":"6","author":"Lushington G.H.","year":"2006","unstructured":"Lushington GH, Guo JX, Hurley MM.  Acetylcholinesterase: molecular modeling with the whole toolkit.","journal-title":"Curr Top Med Chem"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3390\/molecules14041448","volume":"14","author":"Solomon K.A.","year":"2009","unstructured":"Solomon KA, Sundararajan S, Abirami V.  QSAR studies on N-aryl derivative activity towards Alzheimer\u2019s disease.","journal-title":"Molecules"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"10573","DOI":"10.1073\/pnas.90.22.10573","volume":"90","author":"Arispe N.","year":"1993","unstructured":"Arispe N, Pollard HB, Rojas E.  Giant Maltilevel cation channels formed by Alzheimer disease amyloid P-protein [ABP-(1-40)] in bilayer membranes.","journal-title":"Proc Acad Sci"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1073\/pnas.90.2.567","volume":"90","author":"Arispe N.","year":"1993","unstructured":"Arispe N, Rojas E, Pollard HB.  Alzheimer disease amyloid P-protein forms calcium channels in bilayer membranes: Blockade by tromethamine and duminum.","journal-title":"Proc Natl Acad Sci"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.1073\/pnas.90.17.8209","volume":"90","author":"Etchebemgaray R.","year":"1993","unstructured":"Etchebemgaray R, Ito E, Oka K, Tofel-Grehl B, Gibson GE, Alkon D.  Potassium channel dysfunction in fibroblasts identifies patients with Alzheimer disease.","journal-title":"Proc Natl Acad Sci"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jcc.540020311","volume":"2","author":"Weiner P.","year":"1981","unstructured":"Weiner P, Kollman PJ.  AMBER: Assisted mode1 building with energy refinement. A general program for modeling molecules and their interactions.","journal-title":"J Comput Chem"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/157489311795222428","volume":"6","author":"Prado-Prado F.","year":"2011","unstructured":"Prado-Prado F, Cubiella ME, Xerardo GM.  Review of bioinformatics and QSAR studies of \u03b2-secretase inhibitors.","journal-title":"Curr Bioinform"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.bmc.2010.01.068","volume":"18","author":"Prado F.J.","year":"2010","unstructured":"Prado FJ, Garcia MX, Gonzalez DH.  Multi-target spectral moment QSAR  ANN for anti- parasitic drugs against different parasite species.","journal-title":"Bioorg Med Chem"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1016\/j.bmc.2006.01.072","volume":"14","author":"Fernandez M.","year":"2006","unstructured":"Fernandez M, Caballero J, Tundidor CA.  Linear and nonlinear QSAR study of N-hydroxy-2-[(phenylsulfonyl)amino] acetamide derivatives as matrix metalloproteinase inhibitors.","journal-title":"Bioorg Med Chem"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3892\/mmr.2012.757","volume":"5","author":"Chen P.Y.","year":"2012","unstructured":"Chen PY, Tsai CT, Ou CY.  Computational analysis of novel drugs designed for use as acetylcholinesterase inhibitors and histamine H3 receptor antagonists for Alzheimer\u2019s disease by docking, scoring and  evolution.","journal-title":"Mol Med Rep"},{"key":"ref=19","first-page":"28","volume":"1","author":"Borra N.K.","year":"2013","unstructured":"Borra NK, Kuna Y.  Evolution of toxic properties of anti Alzheimer\u2019s drugs through Lipinski\u2019s rule of five.","journal-title":"Int J Pure App Biosci"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.2174\/138161210792389225","volume":"16","author":"Garcia I.","year":"2010","unstructured":"Garcia I, Fall Y, Gomez G, Humberto GD.  QSAR, docking, and CoMFA studies of GSK3 inhibitors.","journal-title":"Curr Pharm Des"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/j.1460-2075.1990.tb07419.x","volume":"9","author":"Woodgett J.R.","year":"1990","unstructured":"Woodgett JR.  Molecular cloning and expression of glycogen synthase kinase-3\/factor A.","journal-title":"EMBO J"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1021\/ci010243q","volume":"42","author":"Stahura F.L.","year":"2002","unstructured":"Stahura FL, Godden JW, Bajorath J.  Differential Shannon entropy analysis identifies molecular property descriptors that predict aqueous solubility of synthetic compounds with high accuracy in binary QSAR calculations.","journal-title":"J Chem Inf Comput Sci"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/ci0003303","volume":"40","author":"Stahura F.L.","year":"2000","unstructured":"Stahura FL, Godden JW, Bajorath J.  Differential Shannon entropy analysis identifies molecular property descriptors that predict aqueous solubility of synthetic compounds with high accuracy in binary QSAR calculations.","journal-title":"J Chem Inf Comput Sci"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.2174\/156802608786786543","volume":"8","author":"Gonzalez D.H.","year":"2008","unstructured":"Gonzalez DH, Prado PF, Ubeira FM.  Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach.","journal-title":"Curr Top Med Chem"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"9529","DOI":"10.3390\/molecules17089529","volume":"17","author":"Desouza S.D.","year":"2012","unstructured":"Desouza SD, Desouza AM, Desouza CC.  Hologram QSAR models of 4-[(Diethylamino)methyl]-phenol inhibitors of acetyl\/butyrylcholinesterase enzymes as potential anti-alzheimer agents.","journal-title":"Molecules"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1021\/jm900859q","volume":"52","author":"Camps P.","year":"2009","unstructured":"Camps P, Formosa X, Galdeano C.  Pyrano [,2-c]quinoline-6-chlorotacrinee Hybrids as a Novel Family of Acetylcholinesterase- and beta-Amyloid-Directed Anti-Alzheimer Compounds.","journal-title":"J Med Chem"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2298\/JSC110804205A","volume":"77","author":"Marym A.","year":"2012","unstructured":"Marym A, Mahmoud S, Mehdi N.  A quantitative structure\u2013activity relationship study on histamine receptor antagonists using the genetic algorithm\u2013multi-parameter linear regression method.","journal-title":"J Serb Chem Soc"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1423-0127-18-8","volume":"18","author":"Shin H.L.","year":"2011","unstructured":"Shin HL, Josephine WW, Hsuan LL.  The discovery of potential acetylcholinesterase inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies.","journal-title":"J Biomed Sci"},{"key":"ref=29","first-page":"7","author":"Cunha E.F.","year":"2013","unstructured":"Cunha EF, Resende JE, Franca TC.  Molecular modeling studies of piperidine derivatives as new acetylcholinesterase inhibitors against neurodegenerative diseases.","journal-title":"J Chem"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2008-2231-21-47","volume":"21","author":"Farani A.A.","year":"2013","unstructured":"Farani AA, Nadri H, Aliabadi A.  Synthesis, docking and acetylcholinesterase inhibitory assessment of 2-(2-(4-Benzylpiperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with potential anti-Alzheimer effects.","journal-title":"DARU J Pharm Sci"},{"key":"ref=31","first-page":"296","volume":"22","author":"Kuna Y.","year":"2013","unstructured":"Kuna Y, Sake N, Kutagolla P, Kukkarasapalli P.  To design novel lead molecules for the enzyme, AChE associated with Alzheimer\u2019s disease.","journal-title":"Int J Pharm Sci Rev Res"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0896-6273(00)80108-7","volume":"16","author":"Inestrosa N.C.","year":"1996","unstructured":"Inestrosa NC, Alvarez A, Perez CA.  Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer\u2019s fibrils: possible role of the peripheral site of the enzyme.","journal-title":"Neuron"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1006\/jmbi.1997.1245","volume":"272","author":"Alvarez A.","year":"1997","unstructured":"Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC.  amyloid\u2013cholinesterase interactions implications for Alzheimer\u2019s disease.","journal-title":"J Mol Biol"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.3390\/molecules17054811","volume":"17","author":"Ismail M.M.","year":"2012","unstructured":"Ismail MM, Kamel MM, Mohamed LW, Faggal SI.  Synthesis of new indole derivatives structurally related to donepezil and their biological evaluation as acetylcholinesterase inhibitors.","journal-title":"Molecules"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuint.2008.06.005","volume":"53","author":"Pakaski M.","year":"2008","unstructured":"Pakaski M, Kalman J.  Interactions between amyloid and cholinergic mechanisms in Alzheimer\u2019s disease.","journal-title":"Neurochem Int"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1016\/j.bmc.2008.07.068","volume":"16","author":"Zhou X.","year":"2008","unstructured":"Zhou X, Wang XB, Wang T, Kong LY.  Design, synthesis and acetylcholinesterase inhibitory activity of novel coumarin analogues.","journal-title":"Bioorg Med Chem"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.3987\/COM-13-12820","volume":"87","author":"Liu S.J.","year":"2013","unstructured":"Liu SJ, Cui L, Xu L, Wang T.  Design, synthesis, and biological evaluation of 7H-thiazolo [,2-b]-1,2,4-triazin-7-one derivatives as dual binding site acetylcholinesterase inhibitors.","journal-title":"Heterocycles"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jmgm.2005.12.002","volume":"25","author":"Carlos H.T.","year":"2006","unstructured":"Carlos HT, Silva DP, Campo VL, Carvalho I, Taft A.  Molecular modeling, docking and ADMET studies applied to the design of a novel Hybrid for treatment of Alzheimer\u2019s disease.","journal-title":"J Mol Graph Model"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1021\/ct300590v","volume":"9","author":"Lemmin T.","year":"2013","unstructured":"Lemmin T, Bovigny C, Lan\u00e7on D, Dal Peraro M.  Cardiolipin models for molecular simulations of bacterial and mitochondrial membranes.","journal-title":"J Chem Theory Comput"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/protein\/11.9.761","volume":"11","author":"Chaney M.O.","year":"1998","unstructured":"Chaney MO, Webster SD, Kuo YM, Roher AR.  Molecular modeling of the A\u03b21-42 peptide from Alzheimer disease.","journal-title":"Protein Eng"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jmgm.2013.02.003","volume":"41","author":"Li Y.P.","year":"2013","unstructured":"Li YP, Weng X, Ning FX.  3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method.","journal-title":"J Mol Graph Model"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.biomaterials.2013.11.028","volume":"35","author":"Zhang D.","year":"2014","unstructured":"Zhang D, Mattila MP, Shahsavani M, Falk A, Teixeira AI, Herl A.  A 3D Alzheimer\u2019s disease culture model and the induction of P21- activated kinase mediated sensing in iPSC derived neuronsequences.","journal-title":"Biomaterials"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1734-1140(12)70878-2","volume":"64","author":"Ozkay U.D.","year":"2012","unstructured":"Ozkay UD, Can OD, Ozkay Y, Ozturk Y.  Effect of benzothiazole\/piperazine derivative on intracerebroventricular streptozotocin-induced cognitive deficits.","journal-title":"Pharmacol Rep"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2010.01.057","volume":"472","author":"Pinton S.","year":"2010","unstructured":"Pinton S, da Rocha JT, Zeni G, Nogueira CW.  Organo selenium improves memory decline in mice: Involvement of acetylcholinesterase activity.","journal-title":"Neurosci Lett"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1358\/mf.2000.22.2.796070","volume":"22","author":"Ogura H.","year":"2000","unstructured":"Ogura H, Kosasa T, Kuriya Y, Yamanishi Y.  Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats.","journal-title":"Methods Find Exp Clin Pharmacol"}],"container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/161334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T12:59:48Z","timestamp":1563800388000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/161334\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,4,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163815666180417120833","relation":{},"ISSN":["1570-1638"],"issn-type":[{"value":"1570-1638","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}